Talvey™ (talquetamab-tgvs) – New orphan drug approval
August 10, 2023 - Janssen announced the FDA approval of Talvey (talquetamab-tgvs), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Top